Monday, June 2, 2025

Introducing Oxygen Attachment Dissociation - Radically Simplifying Isomer-resolved Lipidomics; Using OAD/CID Dual Fragmentations for In-depth Structural Lipidomics

Dr. Kim Ekroos, Founder, Lipidomics Consulting, and President, International Lipidomics Society; Dr. Hiroshi Tsugawa, Professor, Tokyo University of Agriculture and Technology

Dr. Ekroos: Discover the latest advancements in lipidomics and learn how to illuminate the shadowy lipidome. We are introducing a new technology, oxygen attachment dissociation (OAD), that enables routine analysis of previously uncharted lipid biology.

Dr. Tsugawa: Structural lipidomics is an emerging field that resolves fine lipid structures, including double bond positions. I will discuss the development of a novel OAD/CID-MS/MS platform that combines oxygen attachment and collision-induced dissociation, enabling untargeted SN- and C=C position-resolved lipidomics across multiple lipid classes.

.

Tuesday, June 3, 2025

Practical LCMS – From an Idea to Research and Beyond!

Mike Deible, Ph.D., Principal Investigator, RJ Lee Group

This presentation will cover life with an LCMS, from purchasing to production and research, highlighting key considerations from the perspective of a contract and research lab. It will also delve into the specifics of the research conducted, providing detailed insights into the findings and methodologies used for PFAS sample analysis in non-traditional matrices.

Wednesday, June 4, 2025

Imaging Mass Spectrometry with a MALDI iMScope QT: A Laboratory Revolution

Dr. Pierre Chaurand, Full Professor, Dept of Chemistry, University of Montreal, Montreal, QC, Canada

Imaging mass spectrometry has taken the scientific community by storm, and the need for state-of-the-art instrumentation is critical. Modern MALDI MSI systems need to address sensitivity, mass accuracy, spatial resolution and acquisition speed. I will demonstrate through several examples how the Shimadzu iMScope QT, installed in my laboratory in January 2025, has allowed us to surpass expectations and revolutionized our approach to MSI.

Thursday, June 5, 2025

Advancements in Biopharmaceutical Development: Leveraging Mass Spectrometry for Oligonucleotide Therapeutics

Dr. Pierre-Alexander Mücke, ProtaGene GmbH, Germany

Mass spectrometry (MS) plays a crucial role in characterizing RNA-based therapeutics, including mRNA vaccines, siRNA, and antisense oligonucleotides (ASO). Shimadzu offers a unique combination of hardware and software solutions for RNA-based Therapeutics characterization and in this presentation, Dr. Mücke will discuss his most recent results on mRNA vaccine development and QC analysis for short oligonucleotides (siRNA, ASO) using Shimadzu's state-of-the-art systems, Nexera HPLC and LCMS-9050 Q-TOF MS.